Alert detail
FDA Approval: ONAPGO (APOMORPHINE HYDROCHLORIDE) — Type 5 - New Formulation or New Manufacturer
Policy ID: FDA-NDA214056Specialty: NeurologyAdded: 7/8/2026Effective: 2025-02-03billing update
What changed
New subcutaneous apomorphine solution bills Part B; no J-code yet.
Who’s affected: Neurology billing teams · Effective: 2025-02-03
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.
Not ready to subscribe?
Get the free weekly reimbursement brief for Neurology— the week’s changes and deadlines, delivered to your inbox. No account required.